Abstract library

758 results for "Midgut Carcinoid Tumours".
#1103 Risk and Protective Factors for Midgut Carcinoid Tumours: A Case-Control Study of Prospectively Evaluated Patients
Introduction: The incidence of midgut carcinoid tumours is on the rise, but few studies have investigated risk factors for their occurrence.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Epidemiology/Natural history/Prognosis - Descriptive epidemiology
Presenting Author: Doctor Maria Rinzivillo
#2971 A Retrospective Multicentre Evaluation of the Outcomes and Management of Carcinoid Heart Disease in Patients with Advanced Midgut NETs: A NET-CONNECT Descriptive Study
Introduction: Carcinoid heart disease (CHD) is a poor prognostic factor in neuroendocrine tumours (NETs). However, the extreme variability of diagnostic and treatment approaches reported in literature account for uncertainties on the best management in this selected population.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - others, not specified
Presenting Author: MD, Ph.D. Francesca Spada
#1363 Efficacy of Lutetium-177 DOTA Octreotate Peptide Receptor Radionuclide Therapy in Patients with Advanced Neuroendocrine Tumours and Carcinoid Syndrome Refractory to Somatostatin Analogues
Introduction: Somatostatin Analogues (SSAs) are considered the gold standard treatment in Neuroendocrine Tumours (NETs) and carcinoid syndrome.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Apostolos Koffas
#523 Metastatic Midgut Carcinoid Tumors: 20-years Experience in a Single Center
Introduction: The prognosis of metastatic midgut carcinoids has improved during the last decade, due to the increasing number of therapeutic options.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Prof. Claudio Pasquali
#471 Alterations of Global and Gene-Specific DNA Methylation in Midgut Carcinoids
Introduction: Epigenetic alterations of DNA methylation are known to be associated with the clinical presentation of midgut carcinoids.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Omid Fotouhi
#717 A Pancreatic Metastasis from Carcinoid Midgut Tumor
Introduction: Metastatic lesions to the pancreas are rare.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Clinical cases/reports
Presenting Author: professor Claudio Pasquali
#606 Laparoscopic Resection of Primary Midgut Carcinoid Tumors
Introduction: Laparoscopic intestinal surgery is the preferable technique in the majority of intestinal surgical disorders. However, there is no series reported to date on laparoscopic resection of intestinal midgut carcinoid tumors (MCT) due to the rarity as well as the technical difficulties in resection of the large mesenteric root lymph node mass commonly found in these tumors, and the occasional difficulty in identifying the primary MCT. This is the first series reporting the results of laparoscopic resection of MCT.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Prof. Petachia Reissman
#2061 Midgut Carcinoids Presenting as Subacute Intestinal Obstruction. A Case Report of Territory Care Hospital.
Introduction: Midgut carcinoids are well differentiated neuroendocrine tumors possessing secretary properties releasing various peptides. Over the past few decades, there incidence has been increased. Since countries like Pakistan lack the diagnostic facilities, they are often misdiagnosed.
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Case reports
Presenting Author: Dr Arooj Fatima
Authors: Fatima A, Zaidi S S A, ...
#508 Differential Expression of Markers in a Midgut Carcinoid Tissue Microarray
Introduction: Molecular mechanisms driving well-differentiated midgut carcinoid (MGC) tumors are not well-established. To pursue higher resolution tumor diagnostics, we studied a panel of markers for their expression in MGC, including: serotonin, FGF2, b-catenin, and E-cadherin, in primary, lymph node, and liver metastases.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Eric Liu
Authors: Liu E, Mikhitarian K, Revetta F, Shi C, ...
#2840 A Real-World Study of Patients with Carcinoid Syndrome at King’s College Hospital on Long-Term Telotristat Therapy
Introduction: Telotristat ethyl is a tryptophan hydroxylase inhibitor that has been shown to be effective against symptoms of carcinoid syndrome refractory to standard somatostatin analogue therapy by directly inhibiting serotonin production. While clinical trials have established short-term efficacy of the drug, we report an exploratory real-world study of 15 patients with metastatic neuroendocrine tumours on long-term Telotristat (median duration=8 months).
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Targeted therapies
Presenting Author: Doctor Shweta Hota
Authors: Hota S, Cananea E, Martin W, Clement D, ...